Joseph Lunyera1, Dinushika Mohottige2, Anastasia-Stefania Alexopoulos3, Hilary Campbell4, C Blake Cameron1, Nicole Sagalla5, Timothy J Amrhein3, Matthew J Crowley3, Jessica R Dietch6, Adelaide M Gordon7, Andrzej S Kosinski8, Sarah Cantrell9, John W Williams10, Jennifer M Gierisch11, Belinda Ear7, Karen M Goldstein10. 1. Duke University School of Medicine, Durham, North Carolina (J.L., C.B.C.). 2. Duke University School of Medicine and Duke University Medical Center, Durham, North Carolina (D.M.). 3. Duke University Medical Center and Durham Veterans Affairs Health Care System, Durham, North Carolina (A.A., T.J.A., M.J.C.). 4. Margolis Center for Health Policy at Duke University, Durham, North Carolina (H.C.). 5. Durham Veterans Affairs Health Care System and Duke University School of Medicine, Durham, North Carolina (N.S.). 6. Stanford University and Veterans Affairs Palo Alto Health Care System, Palo Alto, California (J.R.D.). 7. Durham Veterans Affairs Health Care System, Durham, North Carolina (A.M.G., B.E.). 8. Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina (A.S.K.). 9. Duke University School of Medicine and Duke University Medical Center Library and Archives, Durham, North Carolina (S.C.). 10. Duke University School of Medicine and Durham Veterans Affairs Health Care System, Durham, North Carolina (J.W.W., K.M.G.). 11. Duke University School of Medicine, Durham Veterans Affairs Health Care System, and Duke University, Durham, North Carolina (J.M.G.).
Abstract
BACKGROUND: The risk for nephrogenic systemic fibrosis (NSF) after exposure to newer versus older gadolinium-based contrast agents (GBCAs) remains unclear. PURPOSE: To synthesize evidence about NSF risk with newer versus older GBCAs across the spectrum of kidney function. DATA SOURCES: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science for English-language references from inception to 5 March 2020. STUDY SELECTION: Randomized controlled trials, cohort studies, and case-control studies that assessed NSF occurrence after GBCA exposure. DATA EXTRACTION: Data were abstracted by 1 investigator and verified by a second. Investigator pairs assessed risk of bias by using validated tools. DATA SYNTHESIS: Of 32 included studies, 20 allowed for assessment of NSF risk after exposure to newer GBCAs and 12 (11 cohort studies and 1 case-control study) allowed for comparison of NSF risk between newer and older GBCAs. Among 83 291 patients exposed to newer GBCAs, no NSF cases developed (exact 95% CI, 0.0001 to 0.0258 case). Among the 12 studies (n = 118 844) that allowed risk comparison between newer and older GBCAs, 37 NSF cases developed after exposure to older GBCAs (exact CI, 0.0001 to 0.0523 case) and 4 occurred (3 confounded) after exposure to newer GBCAs (exact CI, 0.0018 to 0.0204 case). Data were scant for patients with acute kidney injury or those at risk for chronic kidney disease. LIMITATIONS: Study heterogeneity prevented meta-analysis. Risk of bias was high in most studies because of inadequate exposure and outcome ascertainment. CONCLUSION: Although NSF occurrence after exposure to newer GBCAs is very rare, the relatively scarce data among patients with acute kidney injury and those with risk factors for chronic kidney disease limit conclusions about safety in these populations. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs. (PROSPERO: CRD42019135783).
BACKGROUND: The risk for nephrogenic systemic fibrosis (NSF) after exposure to newer versus older gadolinium-based contrast agents (GBCAs) remains unclear. PURPOSE: To synthesize evidence about NSF risk with newer versus older GBCAs across the spectrum of kidney function. DATA SOURCES: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science for English-language references from inception to 5 March 2020. STUDY SELECTION: Randomized controlled trials, cohort studies, and case-control studies that assessed NSF occurrence after GBCA exposure. DATA EXTRACTION: Data were abstracted by 1 investigator and verified by a second. Investigator pairs assessed risk of bias by using validated tools. DATA SYNTHESIS: Of 32 included studies, 20 allowed for assessment of NSF risk after exposure to newer GBCAs and 12 (11 cohort studies and 1 case-control study) allowed for comparison of NSF risk between newer and older GBCAs. Among 83 291 patients exposed to newer GBCAs, no NSF cases developed (exact 95% CI, 0.0001 to 0.0258 case). Among the 12 studies (n = 118 844) that allowed risk comparison between newer and older GBCAs, 37 NSF cases developed after exposure to older GBCAs (exact CI, 0.0001 to 0.0523 case) and 4 occurred (3 confounded) after exposure to newer GBCAs (exact CI, 0.0018 to 0.0204 case). Data were scant for patients with acute kidney injury or those at risk for chronic kidney disease. LIMITATIONS: Study heterogeneity prevented meta-analysis. Risk of bias was high in most studies because of inadequate exposure and outcome ascertainment. CONCLUSION: Although NSF occurrence after exposure to newer GBCAs is very rare, the relatively scarce data among patients with acute kidney injury and those with risk factors for chronic kidney disease limit conclusions about safety in these populations. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs. (PROSPERO: CRD42019135783).
Authors: Mary M Flynn; Anjali N Parekh; Mehul R Parikh; Akhil Sood; Katherine M Shaffer; Thomas M Runge; Anna M Lipowska; Sebastian D Perez; Sonali S Sakaria; Ram M Subramanian Journal: Transplantation Date: 2019-06 Impact factor: 4.939
Authors: T R Elmholdt; M Pedersen; B Jørgensen; K Søndergaard; J D Jensen; M Ramsing; A B Olesen Journal: Br J Dermatol Date: 2011-10 Impact factor: 9.302
Authors: Katherine M Shaffer; Mehul R Parikh; Thomas M Runge; Sebastian D Perez; Sonali S Sakaria; Ram M Subramanian Journal: Liver Transpl Date: 2015-11 Impact factor: 5.799
Authors: Emmanuil Smorodinsky; David S Ansdell; Zeke W Foster; Sameer M Mazhar; Irene Cruite; Tanya Wolfson; Sebastian B Sugay; Gabriella Iussich; Masoud Shiehmorteza; Yuko Kono; Alexander Kuo; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2014-05-09 Impact factor: 4.813
Authors: Richard Bruce; Andrew L Wentland; Anna K Haemel; Robert W Garrett; Donna R Sadowski; Arjang Djamali; Elizabeth A Sadowski Journal: Invest Radiol Date: 2016-11 Impact factor: 6.016
Authors: Martin R Prince; Hae Giu Lee; Chang-Hee Lee; Sung Won Youn; In Ho Lee; Woong Yoon; Benqiang Yang; Haiping Wang; Jin Wang; Tiffany Ting-Fang Shih; Guo-Shu Huang; Jiing-Feng Lirng; Petra Palkowitsch Journal: Eur Radiol Date: 2016-03-09 Impact factor: 5.315
Authors: Thomas G Saba; Gabrielle C Geddes; Stephanie M Ware; David N Schidlow; Pedro J Del Nido; Nathan S Rubalcava; Samir K Gadepalli; Terri Stillwell; Anne Griffiths; Laura M Bennett Murphy; Andrew T Barber; Margaret W Leigh; Necia Sabin; Adam J Shapiro Journal: Orphanet J Rare Dis Date: 2022-09-09 Impact factor: 4.303